Glowise editorial guide

Does Semaglutide Increase Heart Rate? What the Numbers Mean

Semaglutide can raise resting heart rate. Understand product-specific trial results, how to check your pulse, smartwatch limits, and when to seek care.

Portrait of Maya Lee, Glowise Senior GLP-1 Content Editor

Maya Lee

Glowise Senior GLP-1 Content Editor

Published November 13, 20267 min read
Download the Glowise App

Share this guide

Xfin
An adult sitting quietly at a table, checking their wrist pulse with two fingers beside a simple clock

Yes. Semaglutide can increase heart rate, including while you are resting. U.S. prescribing information reports average increases of a few beats per minute in particular trials. That finding does not tell you what caused a new pounding sensation, whether your rhythm is regular, or whether a particular reading is safe for you.

If you have a suddenly very high or very low heart rate for you, especially with chest pain, shortness of breath, dizziness or fainting, call 911. Do not delay care to collect another watch reading. The American Heart Association's emergency guidance is based on the change and symptoms, not a single universal number.

What the current U.S. semaglutide labels actually report

Check both the brand and the form on your prescription. These results describe different trials; they are not a ranking of which product is safest for your heart.

Product and evidenceHeart-rate finding
Wegovy injection, adult weight-reduction trialsMean resting heart rate was 1–4 beats per minute higher than with placebo.
Wegovy tabletsThe label reports similar findings in a tablet trial; do not substitute diabetes-tablet numbers for this result.
Ozempic injection, placebo-controlled trials in adults with type 2 diabetesWith 0.5 mg and 1 mg, mean heart rate rose 2–3 beats per minute; placebo fell 0.3.
Rybelsus trial evidence in the current Rybelsus/Ozempic tablets label, adults with type 2 diabetesWith semaglutide tablets 7 mg and 14 mg, mean heart rate rose 1–3 beats per minute; placebo showed no change.

Sources: current U.S. prescribing information for Wegovy, Ozempic injection, and Rybelsus/Ozempic tablets. The last label covers two tablet formulations; its quoted results come from the Rybelsus studies. Different tablet strengths are not interchangeable milligram for milligram.

An average also hides variation. In adult Wegovy injection weight-reduction trials, maximum changes from baseline at any visit reached 10–19 beats per minute in 41% versus 34% with placebo, and at least 20 in 26% versus 16%. These are maximum visit changes, not the percentage with a continuously racing heart or a diagnosed arrhythmia.

A rise of “only a few beats” cannot be used to dismiss symptoms. Equally, a larger watch change does not establish that semaglutide caused a rhythm disorder. The measurement, its timing and the rest of the clinical picture still matter.

A resting pulse, palpitations and a watch estimate answer different questions

A resting pulse is a rate measured under resting conditions. It counts how many beats occur per minute while you are sitting or lying quietly. A reading immediately after stairs, rushing or exercise is not a useful comparison with a calm resting reading.

Palpitations are a sensation. You might describe fluttering, pounding, skipped beats or a racing feeling. The National Heart, Lung, and Blood Institute describes these sensations among possible arrhythmia symptoms, but having the sensation alone does not diagnose an arrhythmia. Do not assume it is anxiety, and do not dismiss it because a later pulse count looks ordinary. An episode may have ended before you measured it.

A watch reading is device data. A displayed heart rate, a calculated resting-rate trend and an irregular-rhythm notification are different outputs. For example, Apple explains that its optical sensor estimates rate from blood-flow changes at the wrist, and that occasional abnormally high or low readings can appear. A trend can help you describe a change, but it cannot by itself explain its cause.

An irregular-rhythm alert also needs clinical interpretation. Apple's irregular-rhythm instructions say notifications are potential findings rather than a complete diagnosis, and that the feature does not detect every episode of atrial fibrillation. No alert is not an all-clear. A companion tracking app likewise cannot diagnose your rhythm.

How to check a resting pulse you can meaningfully compare

If you feel well enough to check and have no emergency symptoms:

  1. Sit or lie quietly. Let recent exertion settle rather than treating a post-exercise reading as your baseline.
  2. Place your index and middle fingers lightly on the artery at the inside of your wrist.
  3. Count the beats for a full 60 seconds. Note whether the spacing feels regular or uneven; a home count cannot identify the rhythm.
  4. Record the number, time, position and any symptoms. Mark whether it was a manual count or a device reading.

The wrist method follows American Heart Association guidance. Comparing readings taken in similar circumstances is more useful than comparing a quiet morning pulse with an afternoon number after activity. If a watch result is unexpected, check its fit and follow its measurement instructions; if you feel well, a manual count gives you another observation to share. Neither method replaces assessment of symptoms.

For many adults, resting heart rate is 60–100 beats per minute, but fitness, medicines and other circumstances affect it. That reference range is not a rule for continuing semaglutide. A new persistent rise can deserve review even when the number remains inside it. Ask your prescriber how often to check and what changes should trigger contact for you.

When to contact your prescriber—and what Wegovy specifically requires

Contact your prescriber about new, recurrent palpitations, an uneven pulse, or repeated resting readings that are faster than usual. You do not need proof that the medicine caused them before reporting them.

For Wegovy injection or tablets, the prescribing information and Medication Guide give a specific plan: check heart rate regularly during treatment; report palpitations or racing at rest, including chest pounding or racing lasting several minutes. For a sustained increase in resting heart rate, the prescribing information says to discontinue Wegovy. Contact your prescriber promptly about persistent elevation and next-dose instructions rather than waiting for a routine follow-up.

The label does not define “sustained” as a universal increase of 10 beats per minute, or as a particular number of home readings. Do not turn the trial categories into your own stopping threshold. A watch alert alone also does not establish that this label condition has been met. For another semaglutide product, your clinician needs to apply its own label and your circumstances rather than copying the Wegovy instruction across brands.

A useful message is brief and concrete: “I take this brand, form and dose. Since this date, these are my resting measurements and how I took them. I also felt this symptom for this long.” Include dose changes, other medicines or supplements, recent illness, vomiting or diarrhea, and caffeine or stimulant use. These details help distinguish a medication effect from another contributor; they do not prove one explanation.

Your clinician may use an ECG to examine the heart's electrical activity, blood tests where appropriate, or a longer-term monitor if episodes come and go. The NHLBI's diagnostic guidance explains why a pulse number and a rhythm evaluation have different jobs. If symptoms become severe—particularly chest pain or trouble breathing—seek emergency care rather than waiting for a reply.

How can a higher pulse coexist with cardiovascular benefit?

Heart rate and long-term cardiovascular events are different outcomes. In the SELECT randomized trial, 17,604 adults aged 45 or older with established cardiovascular disease, a BMI of at least 27 and no diabetes received weekly semaglutide 2.4 mg or placebo. Over a mean follow-up of about 40 months, cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.5% versus 8.0%—a 20% relative reduction in that combined outcome.

That result supports a benefit for the studied population. It cannot clear an individual's new palpitations, establish safety for every rhythm disorder, or cancel a product's heart-rate warning. Both findings can be true: semaglutide can improve cardiovascular outcomes in an appropriate population, and a persistent resting-pulse increase still needs the action specified for the product you take.

Portrait of Maya Lee, Glowise Senior GLP-1 Content Editor

About the author

Maya Lee

Glowise Senior GLP-1 Content Editor

Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.

She helps readers ask better questions and keep the details relevant to a care conversation together.

See more Glowise on Google

Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.

Glowise library

Bring your GLP-1 routine into one place.

Download the Glowise app to keep medication, meals, hydration, side effects, and progress together.